Samir abai

Radiation Oncologist Consultant , KKUMC| COC-AIPH| ACH| CFB-UNICANCER | CLCC of Sétif | CLCC of Oran

[Samir abai @AbaiSamir]

Very pleased to have attended the SFRO congress again,
Very rewarding .

[Piet Ost @piet_ost]

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.

[Samir abai @AbaiSamir]

Dear Doctors hello,

We would be very happy if you are able to complete this survey especially those who are radiation oncologists.

https://t.co/jxA5Jknkck

Thank you in advance.

[Joe Y Chang @JoeChangMD]

The first phase III randomized clinical study showed proton-based IMPT is better than photon-based IMRT in reducing TX related toxicities without compromising PFS (numerically better) in Head/Neck cancer. @MDAndersonNews @SJFrankMD

[David Sher @DavidSherMD]

No other word for this study other than "amazing."

Thrilled to see that the phase III will start over the summer.

[Arndt Vogel @ArndtVogel]

🔥PLENARY Session #ASCO24🔥
Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus
🔎 ESOPEC phase III trial, 438 patients
👉R0 180 vs 171
👉pCR 17 vs 10%
👉mOS 66 vs 37 mo
👉3yr OS: 57.4 vs 50.7%
🧐FLOT improves OS compared to CROSS
@myESMO

[Yüksel Ürün @DrYukselUrun]

⭕️PSMA-PET nomograms based on PROMISE criteria were more accurate in predicting overall survival for prostate cancer patients than clinical risk scores like STARCAP, EAU, and NCCN.
@asco #asco24 @oncoalert @Uromigos @OncLive @CParkMD @APCCC_Lugano #prostatecancer

[C. Jillian Tsai, MD, PhD @CJTsaiMDPhD]

‼️🚨Happening now - HN oral abstracts #ASCO24
Much anticipated Ph3 IMPT vs IMRT for OPC presented by @SJFrankMD @MDAndersonNews
A tremendous effort to complete this trial. 👋
IMPT non-inferior to IMRT in PFS, OS, superior in tox.

@xrtGenomics @imrtlee @seanmmcbride @YaoCMKL
@yaoyu_md @Esanzgarcia @DrMLChua @KaramLab
@Dealmakertech @DanielMaMD @ScottBratman @JJCaudell @safaviaa @HenryParkMD @ajuloorimd @henson_md @RobertFerrisMD @ezrahahn @Dr_AliHosni @ShalinJShahMD

[Krishan Jethwa @KrishanJethwa]

🚨🚨🚨 #ESOPEC🚨🚨🚨

🔥Practice shifting trial🔥

Patients with resectable, locally advanced, esophagus/GEJ adenocarcinoma

Randomized

Peri-op FLOT (FLOT4)
vs
Pre-operative chemoradiation (CROSS)

Congrats to the study investigators!

Let’s dive in!

#ASCO24 @MayoRadOnc

1/

[Shankar Siva @_ShankarSiva]

📢 plenary #ASCO24 LAURA ph III RCT!! 👏🏽👏🏽 @RamalingamMD
➡️ n=216, adjuvant osimertinib after chemoRT for stage III #lungcancer
➡️ astonishing PFS HR 0.16💥
➡️ immature survival outcomes, trend at HR 0.81
➡️ ≥Grade 3 AEs in 35% vs 12%
➡️ crossover to osi allowed
#lcsm #radonc

[Samir abai @AbaiSamir]

https://t.co/HHaO3ltcKl

[Shankar Siva @_ShankarSiva]

1/ Thank you 🙏🏾, patients, families, and investigators, for contributing to the SEISMIC 🫁trial out now @LancetRespirMed - https://t.co/orK2owgN2T. Led by 🫁@DanSteinfort, this international multicentre recruited n=155 trial from 🇦🇺, 🇨🇦, 🇺🇸, 🇳🇱 #radonc @tssmn @PeterMacRadOnc

[Samir abai @AbaiSamir]

https://t.co/TSHrZvxl7d

[Stephen V Liu, MD @StephenVLiu]

PACIFIC-2 does not meet PFS endpoint. Phase III study of concurrent chemoradiation + duvalumab vs CRT alone for stage III NSCLC. Toxicity? Negative interaction? Or due to intrinsically different population: PACIFIC enrolled only those who completed CRT.

https://t.co/RxsPVfJrpR

[Samir abai @AbaiSamir]

https://t.co/bYNlm0zAGb

[Castalia Fernández, MD. @FuenteApolo]

(SACTION-01 study).
Neoadjuvant SBRT24 Gy in 3 daily fractions followed by immunochemotherapy yields unprecedently high MPR and pCR rates in NSCLC without EGFR mutation
https://t.co/auZrKqHSlV
#ESMO23 #radonc @OncoAlert

[Samir abai @AbaiSamir]

https://t.co/NULnElMQEb

[Gustavo @gusviani]

🎙️ Pembrolizumab➕CRT resulted in ⬆️PFS ✖️CRT alone in 👥 w/ newly diagnosed, previously untreated, high-risk, locally advanced #cervicalcancer‼️@OncoAlert #ESMO2023

[Samir abai @AbaiSamir]

https://t.co/GGSpvpJMNv

[Prof Ananya💙 @achoud72.bsky.social @achoud72]

HYPNO trial confirms non-inferiority of 55/20 to conventional fractionation with cisplatin👏🏽 As a registrar 55/20 was our SoC for #headandneck cancer. My favourite study today! #Moderatehypofractionation strikes again! #ASTRO23 @ASTRO_org @SorenBentzen @iaeaorg #optimalcare

[Samir abai @AbaiSamir]

https://t.co/0ffNWwp8NU

[Samir abai @AbaiSamir]

https://t.co/4IiDW7VlbR

[PDBrown @PDBrownOnc]

Definitive Single Frac SBRT Spine Chordoma & Chondrosarc
· 5 Yr LC 90%
· Small series (22 lesions)
· Alternative for selected cases?
https://t.co/huDNKRc0Xs

[Samir abai @AbaiSamir]

https://t.co/vl8SgswzwL

[Paul Sargos @PaulSargos]

🇫🇷GFRU guidelines for the management of biochemical relapse after RP
💙In press, Cancer Treatment Reviews💚
@ZilliThomas
@stephane_supiot
@GFRU_RO
@CarlSalembier
@MarioTerlizziFR
@TalarD
@CrehangeG

https://t.co/6pSX1boYJI

[Samir abai @AbaiSamir]

https://t.co/41DGSrALmR

[Omran Saifi, MD @OmranSaifi]

Hot off the press @RadiotherapyOn1🚨

Which subset of HER2+ breast cancer patients benefit from PMRT after neoadj anti-HER2 targeted therapy?

cN1-3 ->ypN0 => PMRT 🚫 LRR
cN1-3 ->ypN2-3 => PMRT ⬇️ LRR

Should we de-escalate PMRT for HER2+ BC w/ nodal pCR?

https://t.co/scECRjJJrd

[Samir abai @AbaiSamir]

Salvage Stereotactic Reirradiation for Local Recurrence in the Prostat... https://t.co/XyXseIXuhl